Generic Tascenso ODT Availability
Last updated on Apr 10, 2025.
Tascenso ODT is a brand name of fingolimod, approved by the FDA in the following formulation(s):
TASCENSO ODT (fingolimod lauryl sulfate - tablet, orally disintegrating;oral)
-
Manufacturer: CYCLE
Approval date: December 23, 2021
Strength(s): EQ 0.25MG BASE [RLD] -
Manufacturer: CYCLE
Approval date: December 9, 2022
Strength(s): EQ 0.5MG BASE [RLD]
Is there a generic version of Tascenso ODT available?
No. There is currently no therapeutically equivalent version of Tascenso ODT available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tascenso ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stable fingolimod dosage forms
Patent 10,555,902
Issued: February 11, 2020
Inventor(s): Liu Fangyu
Assignee(s): Handa Pharmaceuticals LLCThe present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
Patent expiration dates:
- January 19, 2036✓
- January 19, 2036✓
- January 19, 2036
-
Stable solid fingolimod dosage forms
Patent 10,925,829
Issued: February 23, 2021
Inventor(s): Liu Fangyu
Assignee(s): Handa Neuroscience, LLCThe present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrate in a patient's oral cavity.
Patent expiration dates:
- January 19, 2036✓
- January 19, 2036
-
Stable solid fingolimod dosage forms
Patent 9,925,138
Issued: March 27, 2018
Inventor(s): Liu Fangyu
Assignee(s): Handa Pharmaceuticals, LLCThe present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.
Patent expiration dates:
- January 19, 2036✓
- January 19, 2036
More about Tascenso ODT (fingolimod)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
